Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …

Abstract On November 21, 2018, the FDA approved glasdegib (Daurismo; Pfizer), a small-
molecule Hedgehog inhibitor, in combination with low-dose cytarabine (LDAC) for treatment …

PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in∼ 12% of patients with
acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2 …

This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and
safety vs conventional care regimens (CCRs) in 488 patients age≥ 65 years with newly …

This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia
(AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly …

Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy
historically have poor outcomes. Approximately 12–15% of older patients with AML harbor …

Purpose To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care
(BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid …

In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell
transplantation (HCT) in adults≥ 70 years with hematologic malignancies across the United …

Older patients with acute myeloid leukemia (AML) have high relapse risk and poor survival
after allogeneic hematopoietic cell transplantation (HCT). Younger patients may receive …